Examines CD73's role in cancer diagnosis, suggesting new markers for NF1-associated tumors.
This study investigated the association between CD73 expression and malignant progression in NF1-associated peripheral nerve sheath tumors and evaluated its potential as a diagnostic marker. Histopathological differentiation of atypical neurofibromatous neoplasms of uncertain biological potential (ANNUBP) and low-grade malignant peripheral nerve sheath tumors (MPNST) in patients with NF1 remains challenging. Therefore, reliable adjunctive markers are needed to improve diagnostic accuracy. CD73 is an ectoenzyme with ecto-5'-nucleotidase activity. Recent studies have also suggested that CD73 may promote tumor invasion by facilitating extracellular matrix remodeling, independent of immune suppression. To investigate the role of CD73 in NF1-associated tumors, we analyzed CD73 expression in 57 NF1-associated tumors, including 39 benign neurofibromas (NF), 7 ANNUBP, and 11 MPNST, using immunohistochemistry and reverse transcription- quantitative PCR (RT-qPCR) in selected cases. Most tumors arose in the skin or subcutaneous tissue. Among the four histological subtypes of NF, solitary and diffuse types were mostly negative for CD73 expression (19/20 cases), whereas plexiform and mixed types, which are associated with a higher risk of malignant transformation, more frequently exhibited positive expression. Most ANNUBP cases (6/7 cases) demonstrated low or negative CD73 expression, whereas all MPNST cases were positive, with the majority showing high expression (9/11 cases). CD73 expression was significantly higher in MPNST than in solitary and diffuse types of NF and ANNUBP. RT-qPCR analysis consistently demonstrated a stepwise increase in NT5E(CD73) mRNA expression progressing from benign solitary and diffuse types of NF (0.74 ± 0.33) to ANNUBP (2.93 ± 0.57) and MPNST (9.26 ± 4.89). These findings suggest that CD73 expression increases in association with higher tumor grade and malignant progression in NF1-associated peripheral nerve sheath tumors and may serve as a useful adjunctive marker in pathological diagnosis, particularly in cases where distinguishing ANNUBP from MPNST is challenging.
No takes yet. Share an insight, caveat, or question.
Matsuda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: